Home » Newsletters » BioWorld Science

BioWorld Science

March 22, 2004

View Archived Issues

Recombinant immunotoxins against breast cancer, osteosarcoma and neuroblastoma

Novel lipoxin A4 analogue with enhanced antiinflammatory activity in vivo

Y-27632 inhibits K+- and NE-induced arterial contraction with greater effects seen in SHR

S-Allyl-L-cysteine protects against amyloid-beta peptide-induced neurotoxicity in vitro

SM-13496, a novel atypical antipsychotic, improves learning deficits and cognition in rats

WHO-led program treats 80 million to protect against lymphatic filariasis

Shortage drug Aristospan now available

Greater prevention of breast cancer recurrence with exemestane

Long-term treatment of fistulizing Crohn's disease with infliximab

Osteoprotegerin impairs fracture healing in rat tibia

Dosing under way in Genencor's phase I hepatitis B study

Arachnova to develop MCI-225 for three novel uses

Arakis acquires AD-923

GTx enters collaboration and license agreement with Ortho Biotech for andarine

Washington Hospital, Texas Heart Institute complete Angiogenix studies

CombiMatrix and St. Jude Children's Research Hospital to study H9 flu strain

New dabigatran prodrugs designed by Boehringer Ingelheim researchers

New antibacterial agents identified by GeneSoft team

Novel p38 kinase inhibitors in early development at Roche

Two series of factor Xa inhibitors claimed by Boehringer Ingelheim

Charterhouse presents HSF-1 activators amd their therapeutic use

Pharmacia describes new protein kinase inhibitors, their preparation and use

Panacea enters CRADA with WRAIR for preclinical testing of PAN-811

NexMed updates pipeline progress

HGF enters clinic in Japan

Positive topline results for Ciprofloxacin GR

EcoNail enters phase I study for onychomycosis

Oral delivery of AVI-4557 produces positive results in clinical study

MDI-P shows potential for treatment of sepsis in preclinical study

Proteome Sciences renames German subsidiaries

Intercell and Statens Serum Institut to develop new prophylactic TB vaccine

Fosfluconazole reported well tolerated in healthy volunteers